Abstract: New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal are useful as sweeteners and for the preparation of orally consumed products, such as foods, beverages, pharmaceutical products, topical pharmaceutical products, and feeds containing general-purpose, stable, and safe monatin sodium salt crystals.

Abstract: The present invention relates to a method for stabilizing a labeled antibody in a solution, in which the labeled antibody is stabilized by allowing the labeled antibody to be present together with at least one of amino acid and a derivative thereof in the solution.

Abstract: New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal are useful as sweeteners and for the preparation of orally consumed products, such as foods, beverages, pharmaceutical products, topical pharmaceutical products, and feeds containing general-purpose, stable, and safe monatin sodium salt crystals.

Abstract: New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal are useful as sweeteners and for the preparation of orally consumed products, such as foods, beverages, pharmaceutical products, topical pharmaceutical products, and feeds containing general-purpose, stable, and safe monatin sodium salt crystals.

Abstract: New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal are useful as sweeteners and for the preparation of orally consumed products, such as foods, beverages, pharmaceutical products, topical pharmaceutical products, and feeds containing general-purpose, stable, and safe monatin sodium salt crystals.

Abstract: Crystals of (2R,4R)-monatin potassium salt which exhibit an X-ray powder diffraction pattern having characteristic peaks at diffraction angles 2? of 5.5°, 7.2°, 8.1°, 8.9°, and 16.3°, by powder X-ray diffraction (Cu—K? radiation), are superior in sweetness, preservation stability, solubility, and color stability.

Abstract: The present invention provides a novel crystal of alanine alkyl ester sulfonate having low hygroscopicity and low corrosiveness, which can be produced industrially economically. The present invention provides crystals of alanine alkyl ester sulfonates represented by formula (1): wherein R1 is a methyl group or an ethyl group, provided that when R1 is a methyl group, R2is an ethylphenyl group or a dimethylphenyl group; and when R1 is an ethyl group, R2 is a methyl group, a phenyl group, a chlorophenyl group, an ethylphenyl group, or a dimethylphenyl group.

Abstract: Crystals of (2R,4R)-monatin potassium salt which exhibit an X-ray powder diffraction pattern having characteristic peaks at diffraction angles 2? of 5.5°, 7.2°, 8.1°, 8.9°, and 16.3°, by powder X-ray diffraction (Cu—K? radiation), are superior in sweetness, preservation stability, solubility, and color stability.

Abstract: The present invention provides a novel crystal of alanine alkyl ester sulfonate having low hygroscopicity and low corrosiveness, which can be produced industrially economically. The present invention provides crystals of alanine alkyl ester sulfonates represented by formula (1): wherein R1 is a methyl group or an ethyl group, provided that when R1 is a methyl group, R2is an ethylphenyl group or a dimethylphenyl group; and when R1 is an ethyl group, R2 is a methyl group, a phenyl group, a chlorophenyl group, an ethylphenyl group, or a dimethylphenyl group.

Abstract: The present invention relates to a method of manufacturing aspartyl dipeptide ester compounds, which can be used as sweeteners, and aldehydes that can be used in the manufacturing processes.

Abstract: N-[N-[3-(2-hydroxy-substituted phenyl)propyl]-L-?-aspartyl]-L-phenylalanine 1-methyl ester derivatives, which are useful as sweeteners, may be conveniently produced by subjecting a 2-hydroxychroman derivative having various substituents on the benzene ring and aspartame to a reductive alkylation reaction. These compounds may be purified by subjecting such a derivative containing one or more impurities to a crystallization step to crystallize the same. Further, there are provided a process for producing dialkoxychroman derivatives useful as intermediates for the production of such aspartame derivatives in the above process, and novel dialkoxychroman derivatives thus produced, which are excellent as the production intermediate.

Abstract: The present invention relates to a method of manufacturing aspartyl dipeptide ester compounds, which can be used as sweeteners.

Abstract: N-[N-[3-(3-hydroxy-4-methoxyphenyl)propyl]-L-&agr;-aspartyl]-L-phenylalanine 1-methyl ester useful as a sweetener with a high potency of sweetness, is provided in the crystalline form having a high stability and a good purity which is favorable as a commercial product.

Abstract: The present invention relates to a method of manufacturing aspartyl dipeptide ester compounds, which can be used as sweeteners, and aldehydes that can be used in the manufacturing processes.

Abstract: The present invention relates to a method of manufacturing aspartyl dipeptide ester compounds, which can be used as sweeteners, and aldehydes that can be used in the manufacturing processes.

Abstract: The present invention relates to a method of manufacturing aspartyl dipeptide ester compounds, which can be used as sweeteners.

Abstract: Herein are disclosed a process for producing xylitol of high purity (one-step desalting process) which comprises the steps of (1) removing the solid matter from a culture froth obtained by culturing a xylitol-producing microorganism in an aqueous culture medium, (2) desalting the resulting solid matter-removed culture broth by removing the ionic substances therefrom by means of a cation-exchange resin and an anion-exchange resin, (3) subjecting the resulting desalted solution to the chromatography using a strongly acidic cation-exchange resin to separate the xylitol from the other sugar alcohol(s) and sugar(s), and (4) obtaining the xylitol by separating it at a high purity from the resulting xylitol solution (fraction), and to a similar process (two-step desalting process) but wherein the desalting carried out twice by adding the ion-exclusion step between Steps (1) and (2) of the above-mentioned process, whereby most of the ionic substances are removed, by which processes highly pure xylitol can be obtained

Abstract: N-[N-[3-(3-hydroxy-4-methoxyphenyl)propyl]-L-&agr;-aspartyl]-L-phenylalanine 1-methyl ester useful as a sweetener with a high potency of sweetness, is provided in the crystalline form having a high stability and a good purity which is favorable as a commercial product.

Abstract: The present invention relates to a method of manufacturing aspartyl dipeptide ester compounds, which can be used as sweeteners.

Abstract: The present invention relates to a method of manufacturing aspartyl dipeptide ester compounds, which can be used as sweeteners, and aldehydes that can be used in the manufacturing processes.